Entrada Therapeutics (TRDA) Accumulated Expenses (2020 - 2026)

Entrada Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 54.77% year-over-year to $11.7 million; the TTM figure through Mar 2026 stood at $11.7 million (up 54.77% YoY), while the FY2025 annual figure was $17.7 million, up 32.52% from the prior year.
• Accumulated Expenses was $11.7 million for Q1 2026 at Entrada Therapeutics, down from $17.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $17.7 million in Q4 2025 to a low of $4.5 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $10.6 million across 5 years, with a median of $11.3 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses surged 158.09% in 2023, then declined 24.7% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $7.6 million in 2022, then surged by 49.49% to $11.3 million in 2023, then grew by 17.82% to $13.3 million in 2024, then jumped by 32.52% to $17.7 million in 2025, then sank by 33.66% to $11.7 million in 2026.
• The last three Accumulated Expenses figures came in at $11.7 million (Q1 2026), $17.7 million (Q4 2025), and $15.5 million (Q3 2025), per Business Quant data.